Shots:
The US FDA has received 510(k) premarket notification for the multi-analyte algorithmic blood test to diagnose Alzheimer’s disease
Submission was backed by data across three independent cohorts & 1,800+ pts, published in the Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring
The blood test uses Quanterix’s Simoa tech to integrate five AD biomarkers (p-Tau217,…
